Please login to the form below

Not currently logged in
Email:
Password:

inVentiv Health wins Pfizer account

Will be tasked with managing the pharma firm’s global clinical services

inVentiv HealthUS pharmaceutical services organisation inVentiv Health has been named by Pfizer as its preferred provider for global clinical services.

The company will oversee Pfizer's sourcing strategy for the clinical operations of all its worldwide business until June 2019, at which point Pfizer may extend the deal for a further two years.

President of the clinical division at inVentiv Health Dr Michael McKelvy, said: "Complex science and challenging marketplace dynamics are driving the need for new, accelerated approaches to clinical development."

He added: "This agreement is an indication that our leading full-service clinical offerings are value-enhancing and scalable. We designed this approach to deliver patient-centric outcomes in an increasingly competitive environment."

As a result of winning Pfizer's clinical operations account, inVentiv Health expanded its clinical operations, with a focus on oncology, pain, neuroscience and respiratory therapeutic areas as well as data and technology-driven efficiency measures.

Gregory Skalicky, chief commercial officer of inVentiv Health's clinical division, said: "The expansion of our relationship under this new preferred provider status will allow us to continue to seamlessly orchestrate our full suite of clinical solutions.

"We're committed to realising improved efficiencies in support of Pfizer's clinical development activities."

Article by
Rebecca Clifford

29th June 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....